Advanced Enzyme Technologies Limited has informed the Exchange about Investor Presentation
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Advanced Enzyme Technologies filed its investor presentation ahead of a DAM Capital Advisors Pharma and Healthcare conference scheduled for September 23, 2025. The presentation highlights the company as India's first and 2nd largest enzyme player globally, with 9 manufacturing units, 7 R&D centers, presence in 45+ countries, and 68+ enzyme/probiotic products. Q1 FY26 results showed strong growth with revenue at ₹1,859 mn (+20% YoY, +11% QoQ), EBITDA at ₹564 mn (+10% YoY, +24% QoQ), and PAT at ₹404 mn (+16% YoY, +51% QoQ), driven by the Human Nutrition segment at ₹1,221 mn. The company highlighted a 5-year addressable market opportunity of ~$4.8 billion across enzymes, probiotics, and bio-catalysis, with the global enzyme market growing at 7.8% CAGR and probiotics at 14.1% CAGR. Key growth strategies include geographical expansion into USA, MENA and Asia, continued R&D investment (~3.9% of FY25 sales), and inorganic expansion through acquisitions of technologies, competencies, and businesses in focus markets.
Positive for shareholders — the strong Q1 FY26 earnings beat, virtually debt-free balance sheet (0.02x net debt/equity), and clear focus on high-growth segments like probiotics and bio-catalysis support the growth narrative. Inorganic expansion plans and continued R&D investment signal management's confidence in scaling the business, though execution risk remains for new product launches and acquisitions.